��ֱ��

Drugs and medicines

Resource

Antiepileptic drugs: review of safety of use during pregnancy

Following the known harms of valproate in pregnancy, MHRA released a report looking into the safety data for epilepsy medicines during pregnancy.

Resource

Brexit and child health - summary of agreements

During the transition period, RCPCH called on Government to put children and young people’s best interest at the centre of its negotiations with the European Union. We summarise and review the agreements made in the UK-EU deal that will impact on child health and our members.

News

Medicines safety alert - Erythromycin therapy

5 January 2021

Erythromycin in babies and infants has been associated with an increased risk of infantile hypertrophic pyloric stenosis.

News

Updated guidance on valproate use in women and girls of childbearing years is published

14 December 2020

This guidance, updated in December 2020 and endorsed by RCPCH, has been produced to inform all healthcare professionals of best practice around the use and prescribing of valproate. It supports them to navigate situations that could arise as a result of prescribing valproate to women during childbea...

Resource

Choosing an oral liquid medicine for children - position statement (endorsed)

We are very pleased to announce the publication of this latest position statement produced by the Neonatal and Paediatric Pharmacy Group (NPPG) and endorsed by the Royal College of Paediatrics and Child Health (RCPCH) regarding how to choose an oral liquid for a child.

Drugs and medicines

Patient safety

News

Medicines safety alert – apraclonidine use in infants below six months of age

17 March 2020

The RCPCH/NPPG Medicines Committee has recently been informed of a severe adverse reaction in a six-month old child with anisocoria who had been administered apraclonidine 1% to help exclude Horner syndrome.

News

E-cigarette use or vaping: reporting suspected adverse reactions

2 March 2020

The Medicines and Healthcare products Regulatory Agency (MHRA) is requesting that healthcare professionals report any suspected side effects or safety concerns with e-cigarettes and the e-liquids used for vaping to the Yellow Card Scheme.

News

��ֱ�� to NICE guidance on cannabidiol use in two forms of childhood epilepsy

5 February 2020

Dr Mike Linney, Registrar and Chair of the Ethics Committee for RCPCH, welcomes recent guidance from NICE, but notes the urgent need for high quality, independent research on this medicine to provide the best possible care for children with complex epilepsy.

Resource

Suspected side effect from a medicine - how to report

The Medicines and Healthcare products Regulatory Agency (MHRA) “Yellow Card Scheme” is the UK system for collecting and monitoring information on suspected safety concerns or incidents involving side effects from medicines (also known as adverse drug reactions or ADRs) and medical devices.

Drugs and medicines

Patient experience

Patient safety

News

Medicines safety alert - domperidone

16 December 2019

Domperidone is no longer licensed for use in children younger than 12 years or those weighing less than 35 kg because of a lack of evidence for benefit.